Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 1.00 |
| ▸ | PPARA | Q07869 | 10/20 | 1.00 |
| ▸ | PPARD | Q03181 | 4/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.61 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-9578 SCHEMBL30475595 | 1.00 | PPARG (1.00) | PPARGPPARAPPARDSOAT1SOAT2 | |
| SCHEMBL20280514 | 1.00 | PPARG (1.00) | PPARGPPARAPPARDSOAT1SOAT2 | |
| SCHEMBL16521916 | 0.93 | PPARG (0.87) | PPARGPPARAPPARDSOAT1SOAT2 | |
| SCHEMBL17471275 | 0.92 | PPARG (0.85) | PPARGPPARAPPARDSOAT1 | |
| SCHEMBL6545314 | 0.91 | PPARG (0.82) | PPARGPPARAPPARDSOAT1SOAT2 | |
| SCHEMBL6356255 | 0.91 | PPARG (0.82) | PPARGPPARAPPARDSOAT1SOAT2 | |
| SCHEMBL6552204 | 0.90 | PPARG (0.81) | PPARGPPARAPPARDSOAT1 | |
| SCHEMBL6744450 | 0.86 | PPARG (0.76) | PPARGPPARAPPARDSOAT1SOAT2 | |
| SCHEMBL6747512 | 0.85 | PPARG (0.73) | PPARGPPARAPPARDSOAT1SOAT2 | |
| SCHEMBL8159724 | 0.84 | PPARA (1.00) | PPARGPPARAPPARDSOAT1SOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034761-A1 | REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS | MASCARENHAS DESMOND (US) | 2024-02-01 | — | — | US | claimed |
| CN-116568802-A | In vitro method for preparing mature red blood cells | 西湖生物医药科技(上海)有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2022192042-A2 | REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS | MASCARENHAS DESMOND (US) | 2022-09-15 | — | — | WO | claimed |
| EP-2981522-A1 | PPAR AGONISTS | Salk Institute for Biological Studies (US) | 2016-02-10 | — | — | EP | claimed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | claimed |
| WO-2014165827-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-10-09 | — | — | WO | claimed |
| WO-2014015318-A1 | SOLUBLE COMPOUNDS FOR IMPROVED GENE THERAPY METHODS | BLUEBIRD BIO, INC. (US) | 2014-01-23 | — | — | WO | claimed |
| US-20100240627-A1 | COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | UNIVERSITEIT GENT | 2010-09-23 | — | — | US | claimed |
| US-20090111782-A1 | COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | GHENT UNIVERSITY (BE) | 2009-04-30 | — | — | US | claimed |
| US-20070065471-A1 | Cosmetic/dermatological applications of PPAR receptor activators | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2007-03-22 | — | — | US | claimed |
| EP-1569640-A4 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1569640-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1149063-B1 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030212138-A1 | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | US | claimed |
| WO-2003059294-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| US-6306854-B1 | ARYLTHIOALKYLACIDS AND ALKYL UREAS | GLAXOSMITHKLINE | 2001-10-23 | — | — | US | claimed |
| US-20240345069-A1 | BROWN ADIPOCYTE PROGENITORS IN HUMAN SKELETAL MUSCLE | ENERGESIS PHARMACEUTICALS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-6306854-B1 | ARYLTHIOALKYLACIDS AND ALKYL UREAS | GLAXOSMITHKLINE | 2001-10-23 | — | — | US | disclosed |
| WO-2000023407-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212138-A1 | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20160023991-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20070065471-A1 | Cosmetic/dermatological applications of PPAR receptor activators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | SLC10A1, OAT, GOT2 | PPARG 249/4885PPARA 608/4885PPARD 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.